WO2026038120 - SYNTHESIS AND CRYSTALLINE FORMS OF A CDK2 INHIBITOR
National phase entry is expected:
Publication Number
WO/2026/038120
Publication Date
19.02.2026
International Application No.
PCT/IB2025/058142
International Filing Date
11.08.2025
Title **
[English]
SYNTHESIS AND CRYSTALLINE FORMS OF A CDK2 INHIBITOR
[French]
SYNTHÈSE ET FORMES CRISTALLINES D'UN INHIBITEUR DE CDK2
Applicants **
NOVARTIS AG
Inventors
CASTAGNOLI, Carlo
HARDEGGER, Leo Albert
KORDIKOWSKI, Andreas
Priority Data
63/682,044
12.08.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3166 | |
| EPO | Filing, Examination, Granting | 24535 | |
| Japan | Filing, Examination, Granting | 3081 | |
| South Korea | Filing, Examination, Granting | 3957 | |
| USA | Filing, Examination, Granting | 12740 |
Total:
47,479
Contact Us
Abstract[English]
The invention generally relates to crystalline forms of the CDK2 inhibitor 2'-((3-ethoxy-1H-pyrazol- 4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]- 6'(7'H)-one or a salt and/or solvate thereof, the synthesis thereof, as well as methods of using the forms in the treatment of cancer.[French]
L'invention concerne de manière générale des formes cristallines de l'inhibiteur de CDK2 2'-((3-éthoxy-1H-pyrazol-4-yl)amino)-7'-((1R,3R)-3-hydroxycyclohexyl)spiro[cyclopropane-1,5'-pyrrolo[2,3-d]pyrimidin]-6'(7'H)-one ou d'un sel et/ou solvate de celui-ci, la synthèse du composé, ainsi que des procédés d'utilisation de ces formes dans le traitement du cancer.